Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Tablet Health Tirzepatide Review: Cost, a Verified Seal & Honest Verdict (2026)

An honest 2026 review of Tablet Health tirzepatide — a genuinely verified LegitScript seal, four named pharmacies, and a cleared warning-letter claim.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

He & She MD

He & She MD is a nationwide telehealth weight-loss clinic offering doctor-prescribed GLP-1 medications: compounded semaglutide and tirzepatide (injectable or oral), with brand-name…

$299/mo (month to month, compounded; every lower rate is a prepaid term)

Check He & She MD availability

Tablet Health has a genuine LegitScript seal (#70456) served directly from LegitScript's own CDN, alongside four named compounding pharmacy partners. Every fact here comes from the company's own published program.

The warning-letter claim, checked and cleared

An earlier version of this review repeated an unconfirmed warning-letter claim against Tablet Health, dated 19 March 2025. That claim is withdrawn, and this section is the correction. Two things are now settled. First, no FDA warning letter is on record for this company: on 7 August 2026 FDA's complete index was paged in full — all 3,651 rows — and matched offline on the company column, the column FDA itself files a letter under. Tablet Health does not appear in it. SkinnyRx's own February 2026 letter returned in that same pass as a positive control, so the zero is a result rather than a search that quietly failed. Second, the date attached to the old claim was never an enforcement date at all: 19 March 2025 is the day FDA ended tirzepatide enforcement discretion, a category-wide policy event that applies to compounded tirzepatide generally and says nothing about any one company. To be exact about what this establishes: as of 7 August 2026 FDA's own warning-letter database holds no warning letter on file for Tablet Health. It is not a verdict on the company in any other respect — the trade-offs below still stand.

§ Tablet Health — Verified Seal, and a Cleared Warning-Letter Claim

ItemDetail
LegitScript seal#70456, against LegitScript's CDN
Tirzepatide$179-$299/mo range
FDA warning letterNo warning letter on record — company-column match against FDA's full index, 7 Aug 2026
Verified: LegitScript seal #70456. FDA's complete index (3,651 rows) was matched on the company column on 7 August 2026: zero results, in a pass where SkinnyRx's own letter returned as a positive control.

What Tablet Health is

Tablet Health is a DTC telehealth platform, offering compounded semaglutide and tirzepatide in both injection and oral forms, plus ED and NAD+ wellness lines. LegitScript certified. It names four compounding pharmacy partners — Pharmacy Hub, Epiq Scripts, Dr. TelX, and Emerad — none of which has an FDA warning letter of its own, per the ranking's research.

What Tablet Health costs

Mid-tier pricing runs $179-$299/month across all four product variants, with no commitment and cancel-anytime terms.

The brand-vs-compounded question

Tablet Health dispenses compounded semaglutide and tirzepatide, in both injectable and oral forms. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Tablet Health's real strengths: a genuinely verified LegitScript seal, plus four named compounding pharmacies, an oral GLP-1 option for both molecules — uncommon in compounded telehealth, and no-commitment, cancel-anytime terms. The trade-offs: states served aren't published — you must complete the intake quiz to learn eligibility, no founder, CEO, medical director, or pharmacist-in-charge is named anywhere, no BBB profile was found, and its own Queens, NYC pharmacy is "opening soon" — all current dispensing routes through external partners. What is no longer a trade-off is the regulatory claim: no FDA warning letter is on record for this company, checked against FDA's complete index on the company column. As with any GLP-1 program, confirm your state's coverage during intake; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Tablet Health's genuinely verified LegitScript seal and four named pharmacy partners are real strengths this review confirmed directly, and FDA's own index holds no warning letter for this company, so the claim this site once left standing is withdrawn. Do confirm your state's eligibility, since it is gated behind the intake. For a provider with named clinical leadership as well, compare it against TeleClinic or Ondra Health. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

Is Tablet Health's LegitScript certification genuine?

Yes — this review confirmed the seal (#70456) is served directly from LegitScript's own CDN.

Does Tablet Health appear in FDA's warning-letter database?

No. FDA's complete index was paged in full on 7 August 2026 and matched offline on the company column: zero results, in a pass where SkinnyRx's own February 2026 letter returned as a positive control. There is no FDA warning letter on record for this company as of that date. The earlier claim, dated 19 March 2025, is withdrawn — that date is the day FDA ended tirzepatide enforcement discretion for the whole category, not an action against this company.

Does Tablet Health name its compounding pharmacies?

Yes — four partners: Pharmacy Hub, Epiq Scripts, Dr. TelX, and Emerad.

References(3)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
  3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2026). Warning Letters (complete index, 3,651 rows paged in full and matched offline on the company column, 7 August 2026 — no entry for Tablet Health). FDA.gov. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.